Standard of Care CAR-T Cell Therapy

CAR-T therapy is a once-off, personalised treatment that uses a patient’s own reprogrammed T-cells to fight their cancer.

Current Treatments (standard of care and clinical trials)

Subsidised access to CAR-T therapy is available for eligible Australian patients with relapsed or refractory Diffuse Large B Cell Lymphoma (DLBCL), and eligible paediatric or young adult (up to 25 years) patients with relapsed or refractory Acute Lymphoblastic Leukaemia (ALL).  The following therapies are currently offered as standard of care:

  • Tisagenlecleucel (Kymriah) ALL and DLBCL
  • Axicabtagene ciloleucel (Yescarta) DLBCL

Further CAR-T therapies for the treatment of additional cancers are under review for approval in 2022 and beyond.

The CoE CIT hosts in a national, weekly CAR-T patient prioritisation meeting where new patient referrals are discussed nationally to ensure fair and equitable access to standard of care CAR-T cell therapies, as well as available clinical trials.

How do I access CAR-T for my patients?

Email: [email protected]